June 23, 2025
Compass Pathways Achieves Phase 3 Win for Psilocybin in Depression, Yet Stock Tumbles
Compass Pathways; COMP360; psilocybin; Phase 3 trial; depression; treatment-resistant depression; clinical trial; stock decline; investor reaction; FDA
Exelixis’ Phase 3 Colorectal Cancer Data Sends Stock Higher
Exelixis; zanzalintinib; colorectal cancer; Phase 3 trial; STELLAR-303; Tecentriq; Regorafenib; clinical trial results; stock surge
Diabetes and Obesity Drug Boom to Propel Lilly and Novo Nordisk to Pharma Sales Leadership by 2030: Evaluate
diabetes; obesity; pharmaceutical sales; Eli Lilly; Novo Nordisk; Evaluate report; top-selling drugs; tirzepatide; semaglutide; Mounjaro; Zepbound; Ozempic; Wegovy; CagriSema; 2030 forecast
Vertex’s Islet Cell Therapy Shows Dramatic Reduction in Dangerous Low Blood Sugar Levels in Type 1 Diabetes Trial
Vertex; islet cell therapy; zimislecel; Type 1 diabetes; hypoglycemia; phase 1/2 trial; endogenous insulin; stem cell therapy